ASPEN: Results of a Phase 3 Randomized Trial of Zanubrutinib versus Ibrutinib for Patients with Waldenström Macroglobulinemia (ASCO)

For more information about this resource, please submit a medical information request.

Presented at the 2020 Annual Meeting of the American Socuety of Clinical Oncology (ASCO), May 29 - May 31, 2020

Abstract: 8007